# Phase 1 Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cell In Patients With Oral Premalignant Lesions

Source: https://onco.cc/trials/nct07631013/  
OnCo record `nct07631013` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This study tests TROP-2-directed treatment; the registry reports that it is not yet recruiting.

## Summary

The registry lists NCT07631013 as not yet recruiting, last updated 2026-06-11. Enrolment is 36 planned participants, an estimate. Interventions: TROP2 CAR/IL-15 TGFBR2 KO NK cells. Primary measures include Safety and Adverse Events (AEs). No results are posted in the registry; this does not exclude separate publications.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-10-06
- Registry id: NCT07631013
- Phase: 1
- Setting: Phase 1 Dose Escalation And Expansion Study Of Intralesional TROP2-CAR/ IL15 TGFBR2 KO Engineered Cord Blood-Derived NK Cells In Patients With Diffused Or Multifocal Oral Premalignant Lesions
- Sponsor: M.D. Anderson Cancer Center

## Sources

- ClinicalTrials.gov NCT07631013: https://clinicaltrials.gov/study/NCT07631013

## Connected records

- targets: [TROP2](https://onco.cc/targets/trop2/)

---
JSON: https://onco.cc/api/v1/entities/nct07631013.json